Antibody Drug Conjugates ADCs

The inventive step: antibody-drug conjugates

Monday 8 April 2013

Interviewee/Contributer: John Lambert

Organisation: ImmunoGen Inc

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Antibodies and ADCs lead cancer pipeline

Saturday 19 May 2012

Interviewee/Contributer: Bruno Pagliara

Organisation: On-Kos Pharma Consulting

Full text available to subscribers only. Click here for information on subscribing to MedNous.

ADCs propelled back into the oncology spotlight

Monday 14 November 2011

Interviewee/Contributer: Karen Finn

Organisation: MedNous

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Why Oxford BioTherapeutics is targeting ADCs

Sunday 13 November 2011

Interviewee/Contributer: Christian Rohlff

Organisation: Oxford BioTherapeutics Ltd

Full text available to subscribers only. Click here for information on subscribing to MedNous.

How developers approach antibody drug conjugates

Saturday 12 November 2011

Interviewee/Contributer: Bruno Pagliara

Organisation: On-kòs Pharma Consulting

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Syndicate content